Literature DB >> 16254173

Policy. OPV cessation--the final step to a "polio-free" world.

R Bruce Aylward1, Roland W Sutter, David L Heymann.   

Abstract

The 20-year, U.S. $4 billion-dollar international effort to eradicate wild polioviruses now includes monovalent oral poliovirus type 1 vaccine (mOPV1), which was first given to 40 million children in India in April 2005. As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis. This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254173     DOI: 10.1126/science.1115547

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  13 in total

Review 1.  Polio: an end in sight?

Authors:  Toby Reynolds
Journal:  BMJ       Date:  2007-10-27

2.  Global eradication of polio: the case for "finishing the job".

Authors:  Chandrakant Lahariya
Journal:  Bull World Health Organ       Date:  2007-06       Impact factor: 9.408

3.  Free, at last! The progress of new disease eradication campaigns for Guinea worm disease and polio, and the prospect of tackling other diseases.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2009-03       Impact factor: 8.807

4.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

5.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

Review 6.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

7.  Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Authors:  Cynthia J Snider; Khalequ Zaman; Concepcion F Estivariz; Mohammad Yunus; William C Weldon; Kathleen A Wannemuehler; M Steven Oberste; Mark A Pallansch; Steven Gf Wassilak; Tajul Islam A Bari; Abhijeet Anand
Journal:  Lancet       Date:  2019-05-16       Impact factor: 79.321

8.  An antiviral peptide inhibitor that is active against picornavirus 2A proteinases but not cellular caspases.

Authors:  Luiza Deszcz; Regina Cencic; Carla Sousa; Ernst Kuechler; Tim Skern
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Potential use of antiviral agents in polio eradication.

Authors:  Armando M De Palma; Gerhard Pürstinger; Eva Wimmer; Amy K Patick; Koen Andries; Bart Rombaut; Erik De Clercq; Johan Neyts
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

10.  Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.